ATE469153T1 - Substituierte 8i-pyridinyldihydrospiro cycloalkyl pyrimido 1,2-a pyrimidin-6-on- und 8i- pyrimidinyldihydrospiro cycloalkyl pyrimido 1,2-a pyrimidin-6-onderivate und deren verwendung bei neurodegenerativen krankheiten - Google Patents

Substituierte 8i-pyridinyldihydrospiro cycloalkyl pyrimido 1,2-a pyrimidin-6-on- und 8i- pyrimidinyldihydrospiro cycloalkyl pyrimido 1,2-a pyrimidin-6-onderivate und deren verwendung bei neurodegenerativen krankheiten

Info

Publication number
ATE469153T1
ATE469153T1 AT04717643T AT04717643T ATE469153T1 AT E469153 T1 ATE469153 T1 AT E469153T1 AT 04717643 T AT04717643 T AT 04717643T AT 04717643 T AT04717643 T AT 04717643T AT E469153 T1 ATE469153 T1 AT E469153T1
Authority
AT
Austria
Prior art keywords
pyrimido
pyrimidine
cycloalkyl
pyrimidinyldihydrospiro
pyridinyldihydrospiro
Prior art date
Application number
AT04717643T
Other languages
German (de)
English (en)
Inventor
Pascal George
Alistair Lochead
Mourad Saady
Franck Slowinski
Philippe Yaiche
Original Assignee
Sanofi Aventis
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Mitsubishi Tanabe Pharma Corp filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE469153T1 publication Critical patent/ATE469153T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04717643T 2003-03-07 2004-03-05 Substituierte 8i-pyridinyldihydrospiro cycloalkyl pyrimido 1,2-a pyrimidin-6-on- und 8i- pyrimidinyldihydrospiro cycloalkyl pyrimido 1,2-a pyrimidin-6-onderivate und deren verwendung bei neurodegenerativen krankheiten ATE469153T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290569A EP1454909B1 (en) 2003-03-07 2003-03-07 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
PCT/EP2004/003051 WO2004078760A1 (en) 2003-03-07 2004-03-05 SUBSTITUTED 8'-PYRIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE AND 8'-PYRIMIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES

Publications (1)

Publication Number Publication Date
ATE469153T1 true ATE469153T1 (de) 2010-06-15

Family

ID=32799103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04717643T ATE469153T1 (de) 2003-03-07 2004-03-05 Substituierte 8i-pyridinyldihydrospiro cycloalkyl pyrimido 1,2-a pyrimidin-6-on- und 8i- pyrimidinyldihydrospiro cycloalkyl pyrimido 1,2-a pyrimidin-6-onderivate und deren verwendung bei neurodegenerativen krankheiten

Country Status (25)

Country Link
US (2) US7294632B2 (enExample)
EP (2) EP1454909B1 (enExample)
JP (1) JP4639182B2 (enExample)
KR (1) KR101069984B1 (enExample)
CN (1) CN100463908C (enExample)
AR (1) AR043485A1 (enExample)
AT (1) ATE469153T1 (enExample)
AU (1) AU2004218250B2 (enExample)
BR (1) BRPI0408189A (enExample)
CA (1) CA2516937C (enExample)
CY (1) CY1111057T1 (enExample)
DE (1) DE602004027354D1 (enExample)
DK (1) DK1603915T3 (enExample)
EA (1) EA008172B1 (enExample)
ES (1) ES2346311T3 (enExample)
IL (1) IL170461A (enExample)
MX (1) MXPA05009574A (enExample)
NO (1) NO20054140L (enExample)
NZ (1) NZ542135A (enExample)
PL (1) PL1603915T3 (enExample)
PT (1) PT1603915E (enExample)
SI (1) SI1603915T1 (enExample)
TW (1) TWI320785B (enExample)
WO (1) WO2004078760A1 (enExample)
ZA (1) ZA200507107B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080025079A (ko) 2005-06-14 2008-03-19 쉐링 코포레이션 아스파르틸 프로테아제 억제제
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1992620A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992625A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone compounds
EP1992621A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992624A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
EP2138485A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
EP2138495A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138498A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted tricyclic derivatives against neurodegenerative diseases
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138492A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
SI2448940T1 (sl) 2009-07-02 2014-10-30 Sanofi Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba
WO2012085244A1 (fr) 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812636A1 (fr) * 2000-08-02 2002-02-08 Novapharme Nouveaux derives 2-phenyl imidazo[1.2-a]pyrimidin-5-ones et 2-phenyl 2,3-dihydro imidazo[1,2-a]pyrimidin-5-ones
EP1184385A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives
ATE269333T1 (de) * 2000-09-01 2004-07-15 Sanofi Synthelabo 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate
EP1184383A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
EP1295884A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
KR100868840B1 (ko) * 2001-09-21 2008-11-14 사노피-아벤티스 신경퇴행성 장애를 위한 치환된2-피리미디닐-6,7,8,9-테트라히드로피리미도[1,2-ａ]피리미딘-4-온 및7-피리미디닐-2,3-디히드로이미다조[1,2-ａ]피리미딘-5(1ｈ)온 유도체
DE60227718D1 (de) * 2001-09-21 2008-08-28 Sanofi Aventis Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives

Also Published As

Publication number Publication date
KR20050106500A (ko) 2005-11-09
AU2004218250A1 (en) 2004-09-16
HK1085740A1 (en) 2006-09-01
CY1111057T1 (el) 2015-06-11
CN1777607A (zh) 2006-05-24
DK1603915T3 (da) 2010-08-30
IL170461A (en) 2011-11-30
TW200510418A (en) 2005-03-16
CA2516937A1 (en) 2004-09-16
AR043485A1 (es) 2005-08-03
JP2006519814A (ja) 2006-08-31
EP1454909A1 (en) 2004-09-08
MXPA05009574A (es) 2006-05-19
EP1603915A1 (en) 2005-12-14
AU2004218250B2 (en) 2010-02-25
EP1454909B1 (en) 2008-08-20
ES2346311T3 (es) 2010-10-14
US7294632B2 (en) 2007-11-13
NO20054140L (no) 2005-12-02
SI1603915T1 (sl) 2010-08-31
NO20054140D0 (no) 2005-09-06
KR101069984B1 (ko) 2011-10-04
PL1603915T3 (pl) 2010-10-29
PT1603915E (pt) 2010-07-22
JP4639182B2 (ja) 2011-02-23
NZ542135A (en) 2008-06-30
CN100463908C (zh) 2009-02-25
DE602004027354D1 (de) 2010-07-08
EP1603915B1 (en) 2010-05-26
BRPI0408189A (pt) 2006-03-21
US20060025431A1 (en) 2006-02-02
US20080081819A1 (en) 2008-04-03
TWI320785B (en) 2010-02-21
US7507743B2 (en) 2009-03-24
EA008172B1 (ru) 2007-04-27
WO2004078760A1 (en) 2004-09-16
EA200501241A1 (ru) 2006-04-28
CA2516937C (en) 2011-10-25
ZA200507107B (en) 2006-11-29

Similar Documents

Publication Publication Date Title
ATE469153T1 (de) Substituierte 8i-pyridinyldihydrospiro cycloalkyl pyrimido 1,2-a pyrimidin-6-on- und 8i- pyrimidinyldihydrospiro cycloalkyl pyrimido 1,2-a pyrimidin-6-onderivate und deren verwendung bei neurodegenerativen krankheiten
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
DE602005004144D1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln
EP1620763A4 (en) ELEMENTS OF MIRRORS FOR VEHICLES AND ASSEMBLIES INCORPORATING THE SAID ELEMENTS
ATE386744T1 (de) Pyrimidoderivate mit antiproliferativer aktivität (ii)
DE502004007000D1 (de) Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE470675T1 (de) Immunoglobulinvarianten und deren verwendungen
ATE458717T1 (de) Beta-amino-alpha-cyanoacrylate und deren verwendung als herbizide
ATE459647T1 (de) Humane il-18 substitutionsmutanten und deren konjugate
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
DE602004023760D1 (de) Kompositstent mit inneren und äusseren stentelementen und anwendungsverfahren
DE602004021037D1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
DE60226704D1 (de) Acylierte 6,7,8,9-tetrahydro-5h-benzocycloheptenyl-amine und deren pharmazeutische verwendung
NO20041142L (no) Subsitituerte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-on og 7-pyrimidinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)on-derivater for neurodegenerative lidelser
ATE524178T1 (de) Acylierte, heteroaryl-kondensierte cycloalkenylamine und deren verwendung als arzneimittel
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
DE60323754D1 (de) Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
DE10251294B4 (de) Polyamidformmasse und deren Verwendung
DE602005011593D1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
DE502005010409D1 (de) Thermoplastische Polyurethane und deren Verwendung
DE602004000159D1 (de) Fahrzeugsitzstruktur und damit ausgerüstetes Fahrzeug
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
ATE491710T1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7- dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1603915

Country of ref document: EP